2Q08 worldwide sales of Isentress, Merck's HIV integrase inhibitor approved in the treatment-experienced setting, were $77M. (Merck launched Isentress in the United States in October 2007.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.